T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas

Cancer

Volumn 123, Issue 17, 2017, Pages 3291-3304

  Pollack, Seth M ^a,b   He, Qianchuan ^a   Yearley, Jennifer H ^c   Emerson, Ryan ^d   Vignali, Marissa ^d   Zhang, Yuzheng ^a   Redman, Mary W ^a   Baker, Kelsey K ^a   Cooper, Sara ^a   Donahue, Bailey ^a   Loggers, Elizabeth T ^a,b   Cranmer, Lee D ^a,b   Spraker, Matthew B ^e   Seo, Y David ^e   Pillarisetty, Venu G ^e   Ricciotti, Robert W ^b   Hoch, Benjamin L ^b   McClanahan, Terrill K ^c   Murphy, Erin ^c   Blumenschein, Wendy M ^c   Townson, Steven M ^c   Benzeno, Sharon ^d   Riddell, Stanley R ^a,b,f   Jones, Robin L ^a,b,g   more..

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Adaptive Biotechnologies Corp   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

gene expression; immunotherapy; leiomyosarcoma; liposarcoma; pleomorphic; programmed cell death protein (PD 1); programmed death ligand 1 (PD L1); sarcoma; T cell receptors

Indexed keywords

FORMALDEHYDE; PARAFFIN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR BETA CHAIN; PDCD1 PROTEIN, HUMAN;

ADULT; AGED; ANTIGEN PRESENTATION; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEDIFFERENTIATED LIPOSARCOMA; HUMAN; IMMUNOHISTOCHEMISTRY; INFORMED CONSENT; LEIOMYOSARCOMA; LIMIT OF QUANTITATION; LIPOSARCOMA; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MYXOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; ROUND CELL LIPOSARCOMA; SYNOVIAL SARCOMA; UNDIFFERENTIATED PLEOMORPHIC SARCOMA; WELL DIFFERENTIATED LIPOSARCOMA; ANALYSIS OF VARIANCE; CANCER STAGING; CELL CLONE; CLUSTER ANALYSIS; CYTOLOGY; DISEASE FREE SURVIVAL; FACTUAL DATABASE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEEDLE BIOPSY; PATHOLOGY; PROGNOSIS; SARCOMA; SOFT TISSUE NEOPLASMS; SURVIVAL ANALYSIS; T LYMPHOCYTE; TUMOR INVASION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BIOPSY, NEEDLE; CLONE CELLS; CLUSTER ANALYSIS; COHORT STUDIES; COMBINED MODALITY THERAPY; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; RETROSPECTIVE STUDIES; SARCOMA; SOFT TISSUE NEOPLASMS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; YOUNG ADULT;

EID: 85018743172     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30726     Document Type: Article

References (46)

1. June CH, Riddell SR, Schumacher TN. Adoptive cellular therapy: a race to the finish line. Sci Transl Med. 2015;7:280ps7.
2. Emens LA, Butterfield LH, Hodi FS Jr, Marincola FM, Kaufman HL. Cancer immunotherapy trials: leading a paradigm shift in drug development. J Immunother Cancer. 2016;4:42.
3. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233-5239.
4. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725-733.
5. Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined CD4+:CD8 + composition in adult B cell ALL patients. J Clin Invest. 2016;126:2123-2138.
6. Robbins PF, Kassim SH, Tran TL, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21:1019-1027.
7. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29:917-924.
8. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189-2199.
9. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454.
10. Seiwert TY, Burtness B, Weiss J, et al. Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1 + head and neck cancer patients [abstract]. ASCO Meeting Abstracts. 2015;33:6017.
11. Ribas A, Robert C, Hodi FS, et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature [abstract]. ASCO Meeting Abstracts. 2015;33:3001.
12. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568-571.
13. Kawaguchi S, Tsukahara T, Ida K, et al. SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: a study from the Japanese Musculoskeletal Oncology Group. Cancer Sci. 2012;103:1625-1630.
14. Bloom JE, McNeel DG, Olson BM. Vaccination using peptides spanning the SYT-SSX tumor-specific translocation. Expert Rev Vaccines. 2012;11:1401-1404.
15. Jungbluth AA, Antonescu CR, Busam KJ, et al. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J Cancer. 2001;94:252-256.
16. Pollack SM, Jungbluth AA, Hoch BL, et al. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer. 2012;118:4564-4570.
17. Somaiah N, Block MS, Kim JW, et al. Phase I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1 [abstract]. ASCO Meeting Abstracts. 2015;33:3021.
18. Kanojia D, Nagata Y, Garg M, et al. Genomic landscape of liposarcoma. Oncotarget. 2015;6:42429-42444.
19. Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4 + T cells in a patient with epithelial cancer. Science. 2014;344:641-645.
20. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339:1546-1558.
21. Tawbi HE. SARC 038: a phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas. Paper presented at: American Society of Clinical Oncology 2016 Annual Meeting; June 3-7, 2016; Chicago, IL.
22. Coindre JM, Terrier P, Bui NB, et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol. 1996;14:869-877.
23. Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26:317-325.
24. Payton JE, Grieselhuber NR, Chang LW, et al. High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples. J Clin Invest. 2009;119:1714-1726.
25. Robins HS, Srivastava SK, Campregher PV, et al. Overlap and effective size of the human CD8 + T cell receptor repertoire. Sci Transl Med. 2010;2:47ra64.
26. Robins HS, Ericson NG, Guenthoer J, et al. Digital genomic quantification of tumor-infiltrating lymphocytes. Sci Transl Med. 2013;5:214ra169.
27. Robins HS, Campregher PV, Srivastava SK, et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood. 2009;114:4099-4107.
28. Lee CH, Espinosa I, Vrijaldenhoven S, et al. Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res. 2008;14:1423-1430.
29. Ganjoo KN, Witten D, Patel M, et al. The prognostic value of tumor-associated macrophages in leiomyosarcoma: a single institution study. Am J Clin Oncol. 2011;34:82-86.
30. Seth D. Pollak: award for distinguished scientific early career contributions to psychology. Am Psychol. 2006;61:805-807.
31. Kim JR, Moon YJ, Kwon KS, et al. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One. 2013;8:e82870.
32. D'Angelo SP, Shoushtari AN, Agaram NP, et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol. 2015;46:357-365.
33. Constantinidou A, Miah A, Pollack S, Jones RL. New drugs and clinical trial design in advanced sarcoma: have we made any progress? Future Oncol. 2013;9:1409-1411.
34. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995;13:1537-1545.
35. Gelderblom H, Blay JY, Seddon BM, et al. Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study. Eur J Cancer. 2014;50:388-396.
36. Judson IR, Verjeij J, Gelderblom H, et al. Result of a randomised phase III trial (EORTC 62012) of single agent doxorubicin versus plus ifosfamide as first line chemotherapy for patients with advanced, soft tissue sarcoma: a survival study by the EORTC Soft Tissue and Bone Sarcoma Group. Oral presentation at: 18th Annual Connective Tissue Oncology Society Meeting; October 30-November 2, 2013; New York, NY.
37. Rajendra R, Jones RL, Pollack SM. Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib. Onco Targets Ther. 2013;6:217-222.
38. van der Graaf WT, Blay JY, Chawla SP, et al; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879-1886.
39. Tawbi HA, Burgess MA, Crowley J, et al. Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): results of SARC028–a multicenter phase II study [abstract]. ASCO Meeting Abstracts. 2016;34:11006.
40. Miao D, Adeegbe D, Rodig SJ, et al. Response and oligoclonal resistance to pembrolizumab in uterine leiomyosarcoma: genomic, neoantigen, and immunohistochemical evaluation [abstract]. ASCO Meeting Abstracts. 2016;34:11043.
41. Espinosa I, Beck AH, Lee CH, et al. Coordinate expression of colony-stimulating factor-1 and colony-stimulating factor-1-related proteins is associated with poor prognosis in gynecological and nongynecological leiomyosarcoma. Am J Pathol. 2009;174:2347-2356.
42. Edris B, Weiskopf K, Volkmer AK, et al. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci U S A. 2012;109:6656-6661.
43. Pollack SM, Jones RL, Farrar EA, et al. Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells. J Immunother Cancer. 2014;2:36.
44. Pollack SM, Li Y, Blaisdell MJ, et al. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine. PLoS One. 2012;7:e32165.
45. Somaiah N, Block MS, Kim JW, et al. Single-agent LV305 to induce anti-tumor immune and clinical responses in patients with advanced or metastatic sarcoma and other cancers expressing NY-ESO-1 [abstract]. ASCO Meeting Abstracts. 2016;34:3093.
46. Pollack S, Kim EY, Conrad EU, et al. Using G100 (glucopyranosyl lipid A) to transform the sarcoma tumor immune microenvironment [abstract]. ASCO Meeting Abstracts. 2016;34:11017.